Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
SG&A Expense Growth
20.34%
Fiscal year · Period ending:
CANF SG&A Expense Growth
Latest reported20.34%period ending
Latest reported20.34%period ending
CANF FY SG&A Growth (YoY) (0.00% → 20.34%)
Latest values, visible window
High-resolution chart · PNG
CANF sg&a expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| 20.3433% | |
| 3.1134% | |
| -5.9815% | |
| -18.2575% | |
| 30.2948% | |
| -3.6565% | |
| -3.0389% | |
| 7.1268% | |
| 9.3619% | |
| -0.1247% | |
| -8.1777% | |
| -34.939% | |
| 82.0895% | |
| 33.3975% | |
| 9.9247% | |
| 0% |